MedPath

Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis

Conditions
Systemic Sclerosis
Arthritis
Registration Number
NCT01834157
Lead Sponsor
Prof. Laszlo Czirjak
Brief Summary

Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and several internal organs. Beside skin involvement, digital ulcers, tendinitis, calcinosis and flexion contractures, the presence of hand arthritis is a major contributor to impairment of hand function in systemic sclerosis. Several immunomodulatory drugs used in other rheumatic diseases (including methotrexate, leflunomide, azathioprine, mycophenolate mofetil and low-dose corticosteroids) can potentially improve arthritis and consequently hand function in systemic sclerosis. For the assessment of arthritis, the CDAI (clinical disease activity index) is validated in rheumatoid arthritis, and may be useful for SSc-related arthritis, too.

This observational trial is part of the collaborative project "DeSScipher", one out of five observational trials to decipher the optimal management of systemic sclerosis. Aim of this observational trial is to:

* investigate the efficacy and safety of different treatments on hand dysfunction in systemic sclerosis patients with hand arthritis and

* to validate the CDAI for arthritis in systemic sclerosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Juvenile and adult Systemic sclerosis patients, with diagnosis according to the ACR/EULAR adult SSc criteria and PRES/ACR/EULAR juvenile SSc criteria respectively
  • Clinical signs of arthritis (defined as ≥2 tender and swollen joints)
Exclusion Criteria
  • Presence of significant, long standing articular pain due to other cause than autoimmune disease
  • Presence of hand disability caused by other, than autoimmune disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of HAQ-DI (CHAQ-DI in jSSc) by at least -0.21 in one year12 months

Improvement from baseline in Health Assessment Questionnaire - Disability Index (Child Health Assessment Questionnaire - Disability Index in juvenile systemic sclerosis) by at least -0,21(moderate improvement) in one year

Secondary Outcome Measures
NameTimeMethod
Improvement of the CHFS in one year12 months

Improvement of the Cochin Hand Function Scale in one year

Improvement of the CDAI in one year12 months

Improvement of the Clinical Disease Activity Index in one year

Improvement of the SDAI in one year12 months

Improvement of the Simplified Disease Activity Index in one year

Improvement of the DAS28(We) in one year12 months

Improvement of the Disease Activity Score 28 (using 4 variables, including erythrocyte sedimentation rate) in one year

Improvement of the DAS28(CRP) in one year12 months

Improvement of the Disease Activity Score 28 (using 4 variables, including C-reactive protein) in one year

Trial Locations

Locations (33)

Universitätshautklinik Köln

🇩🇪

Cologne, Germany

Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica, Università Politecnica delle Marche, Polo Didattico, University of Ancona

🇮🇹

Ancona, Italy

University of Manchester, Rheumatic Diseases Centre, Clinical Sciences

🇬🇧

Manchester,Salford, United Kingdom

Dubrava University Hospital

🇭🇷

Zagreb, Croatia

Universitätsklinikum Erlangen

🇩🇪

Erlangen, Germany

Krankenhaus St. Josef

🇩🇪

Wuppertal, Germany

University of Padova

🇮🇹

Padova, Italy

Assiut and Sohage University Hospital Rheumatology Department Assiut University Hospital

🇪🇬

Assiut, Egypt

Pecsi Tudomanyegyetem - University of Pecs

🇭🇺

Pecs, Hungary

Policlinico, Via Pansini

🇮🇹

Napoli-Italia, Italy

Department of Internal Medicine and Rheumatology Clinic, Ion Cantacuzino Clinical Hospital

🇷🇴

Bucharest, Romania

Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A & INSERM 1016

🇫🇷

Paris, France

Medizinische Universitätsklinik Abt. II

🇩🇪

Tübingen, Germany

Department of Internal Medicine Hôpital Claude Huriez

🇫🇷

Lille cedex, France

University of Ghent, Department of Rheumatology

🇧🇪

Gent, Belgium

Divisione di Reumatologia, Università di Roma La Sapienza, Dipartimento di Clinica e Terapia medica applicata, Policlinico Umberto I

🇮🇹

Roma, Italy

GR.T.Popa Center for Biomedical Research, European Center for Translational Research, "GR.T.Popa" University of Medicine and Pharmacy, Rehabilitation Hospital

🇷🇴

Iasi, Romania

University of Zurich, Department of Rheumatology

🇨🇭

Zurich, Switzerland

Felix-Platter Spital

🇨🇭

Basel, Switzerland

Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology

🇩🇪

Bad Nauheim, Germany

Department of Rheumatology, University of Cagliari-Policlinico Universitario

🇮🇹

Monserrato, Italy

Reumatologie, University of Medicine & Pharmacy,"Iuliu Hatieganu" Cluj

🇷🇴

Cluj-Napoca, Romania

University of Marmara, Department of Rheumatology

🇹🇷

Istanbul, Turkey

Endokrinologikum Frankfurt

🇩🇪

Frankfurt, Germany

University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine

🇮🇹

Firenze, Italy

The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital

🇬🇧

Leeds, United Kingdom

Clinic of Nephrology, Internal and Occupational Diseases

🇷🇺

Moscow, Russian Federation

Hospital Universitario Madrid Norte Sanchinarro

🇪🇸

Madrid, Spain

Institute of Rheumatology, Russian Academy of Medical Science

🇷🇺

Moscow, Russian Federation

Institute of Rheumatology Belgrade

🇷🇸

Belgrade, Serbia

Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie

🇩🇪

Berlin, Germany

Centre for Pediatric Rheumatology, Klinikum Eilbek

🇩🇪

Hamburg, Germany

Royal Free Hospital, University College London

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath